Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

NCT06408857 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

125

Enrollment

OTHER

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: MAM01 300 mg SC
DRUG: MAM01 300 mg IM
DRUG: MAM01 2000 mg IV
DRUG: MAM01 190 mg SC
DRUG: MAM01 225 mg SC
DRUG: MAM01 150 mg SC
DRUG: MAM01 150 mg IM
DRUG: MAM01 150 mg IV
DRUG: Placebo SC
DRUG: Placebo IV
DRUG: Placebo IM

Sponsor

Gates Medical Research Institute